befotertinib   Click here for help

GtoPdb Ligand ID: 12951

Synonyms: compound 4 [WO2019218987A1] [2] | D-0316 | D0316 | Surmana®
Approved drug
befotertinib is an approved drug (China NMPA (2023))
Compound class: Synthetic organic
Comment: Befotertinib (D-0316) is an third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that was developed as a treatment for non-small cell lung cancer (NSCLC) [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 13
Topological polar surface area 84.8
Molecular weight 567.61
XLogP 3.32
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES C=CC(=O)NC1=C(C=C(C(=C1)NC2=NC=CC(=N2)C3=CN(CC(F)(F)F)C4=C3C=CC=C4)OC)N(C)CCN(C)C
InChI InChI=1S/C29H32F3N7O2/c1-6-27(40)34-22-15-23(26(41-5)16-25(22)38(4)14-13-37(2)3)36-28-33-12-11-21(35-28)20-17-39(18-29(30,31)32)24-10-8-7-9-19(20)24/h6-12,15-17H,1,13-14,18H2,2-5H3,(H,34,40)(H,33,35,36)
No information available.
Summary of Clinical Use Click here for help
Befotertinib was approved in China in May 2023, as a second-line treatment for advanced or metastatic, progessing EGFRT790M positive NSCLC [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03861156 D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer Phase 2 Interventional InventisBio Co., Ltd 4
NCT04206072 D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC Phase 2/Phase 3 Interventional Betta Pharmaceuticals Co., Ltd. 5